Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Tien S, Deng BY, Pan XM, Yu HS, Zhou HX, Guo YW, Wu B. Trans-cinnamaldehyde alleviates hepatic steatosis and pyroptosis via SIRT1 activation in acute alcoholic liver injury. World J Hepatol 2026; 18(11): 121224 [DOI: 10.4254/wjh.121224]
Shiuan Tien, Bao-Yi Deng, Xue-Mei Pan, Hong-Sheng Yu, Hao-Xiong Zhou, Yun-Wei Guo, Bin Wu, Department of Gastroenterology, Alcohol-related Liver Disease Center, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, Guangdong Province, China
Shiuan Tien, Bao-Yi Deng, Xue-Mei Pan, Hong-Sheng Yu, Hao-Xiong Zhou, Yun-Wei Guo, Bin Wu, Guangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, Guangdong Province, China
Co-first authors: Shiuan Tien and Bao-Yi Deng.
Co-corresponding authors: Yun-Wei Guo and Bin Wu.
Author contributions: Tien S and Deng BY contributed equally to this work, as they are co-first authors; Tien S executed experiments and analyzed data; Deng BY drafted figures and wrote manuscripts; Pan XM and Yu HS prepared figures; Zhou HX designed the research study; Guo YW supervised and provided conceptual guidance; Wu B conceived the study and provided financial funding; Guo YW and Wu B are co-corresponding authors; all authors contributed to the interpretation of the study and have read and approve the final manuscript.
Supported by the National Natural Science Foundation of China, No. 82070574 and No. 82170604.
Institutional review board statement: The human gene expression data used for theoretical analysis and comparison in this study were sourced from the public database Gene Expression Omnibus (GEO) (Accession Number: GSE28619). All data in this database have undergone ethical review by the data submitter’s institutional ethics committee and obtained participant informed consent prior to public release. This study utilized only these de-identified, publicly available datasets. It did not involve any new patient recruitment, sample collection, or clinical intervention, and therefore did not require additional approval from an Institutional Review Board.
Institutional animal care and use committee statement: All animal experiments were approved by the Institutional Animal Care and Use Committee at the South China Agricultural University (No. 2025H001).
Conflict-of-interest statement: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: No additional data are available.
Corresponding author: Bin Wu, MD, Professor, Department of Gastroenterology, Alcohol-related Liver Disease Center, The Third Affiliated Hospital of Sun Yat-Sen University, No. 600 Tianhe District, Guangzhou 510630, Guangdong Province, China. wubin6@mail.sysu.edu.cn
Received: March 21, 2026 Revised: April 26, 2026 Accepted: October 13, 2026 Published online: November 27, 2026 Processing time: 245 Days and 9 Hours
Abstract
BACKGROUND
Acute alcoholic liver injury (ALI) is a hepatic disorder caused by excessive alcohol intake. The typical pathological features of ALI include hepatic lipid droplet accumulation, hepatocyte death, and inflammatory cell infiltration. Trans-cinnamaldehyde (TCA) is a natural aldehydic organic compound that exerts antibacterial, antioxidant, anti-inflammatory, and lipid metabolism-regulating effects. However, whether TCA can alleviate acute ALI remains unclear.
AIM
To investigate the therapeutic targets of TCA for the treatment of acute ALI through transcriptomic analysis and experimental validation.
METHODS
We established a mouse model of acute ALI in vivo by oral gavage administration of ethanol (5 g/kg, 50% v/v) to investigate the protective effects of TCA against ethanol-induced hepatic steatosis and cell death. In vitro, we explored the mechanisms by which TCA regulates the sirtuin 1/peroxisome proliferator-activated receptor alpha (SIRT1/PPARα) pathway, fatty acid β-oxidation, and pyroptosis through SIRT1 gene silencing.
RESULTS
Our study found that TCA treatment (40 mg/kg) significantly reduced serum alanine aminotransferase and aspartate aminotransferase activities, as well as hepatic total cholesterol and triglyceride levels in mice with acute ALI. Furthermore, TCA treatment markedly attenuated inflammatory cell infiltration, endoplasmic reticulum (ER) stress, and hepatocyte death. Analysis of the Gene Expression Omnibus database (GSE28619) from patients with alcoholic hepatitis revealed significant enrichment of the adenosine 5’-monophosphate-activated protein kinase and PPAR signaling pathways. Mechanistically, TCA activated SIRT1/PPARα signaling. Notably, SIRT1 silencing abrogated the protective effects of TCA against acute ALI, including the amelioration of hepatic steatosis, enhancement of fatty acid β-oxidation, and suppression of ER stress-related proteins such as glucose-regulated protein 78, phosphorylated inositol-requiring enzyme 1α, C/EBP homologous protein and pyroptosis-associated proteins such as NOD-like receptor family pyrin domain containing 3, cleaved cysteinyl aspartate specific proteinase-1 (cleaved caspase-1), N-terminal gasdermin D.
CONCLUSION
TCA alleviated hepatocyte lipid deposition, ER stress and cell death in acute ALI by promoting SIRT1 activity, suggesting that TCA is a potential therapeutic agent for ALI.